ResoTher Pharma

ResoTher Pharma is a private, clinical-stage biotech developing a novel class of peptide therapeutics designed as resolution therapy for inflammatory-driven cardiovascular diseases. The company's lead program is in Phase 2a for myocardial infarction, targeting neutrophil-driven inflammation to terminate the inflammatory response and promote tissue regeneration. ResoTher operates in the high-unmet-need space of acute cardiovascular interventions, leveraging recent clinical discoveries that pinpoint inflammation as a key prognostic determinant. Its strategy is to provide additional therapeutic benefit where current standard of care falls short.

Platform for developing peptide-based drugs that act as resolution therapy, specifically targeting neutrophil-driven inflammation to terminate the inflammatory response and induce tissue regeneration.

ResoTher competes in the inflammation-modulating space for cardiovascular disease. Direct competitors include companies developing other anti-inflammatory biologics (e.g., targeting IL-1β, IL-6). Its key differentiation is the pro-resolving, peptide-based approach aimed at actively ending inflammation and promoting healing, rather than broad immunosuppression. However, it faces the significant market presence and resources of large pharma companies active in cardiology.